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Rheumatoid arthritisAbstract Aim of the work: To analyse interleukin 23 receptors (IL23R) single-nucleotide
polymorphism (SNPs) (rs11209026, rs2201841, and rs10889677) and to detect their association with
Egyptian rheumatoid arthritis (RA) patients.
Patients and methods: The study included 120 Egyptian RA patients and 120 healthy controls
that were genotyped for the three SNPs by real time/polymerase chain reaction for the ﬁrst SNP
and restriction fragment length polymorphism/PCR (RFLP/PCR) in the last two SNPs. The disease
activity score (DAS28) was assessed in the patients.
Results: The studied patients had a mean age of 42.5 ± 13.4 years, a disease duration of
5.2 ± 3.5 years and consisted of 22 males and 98 females. Joint deformities were present in 35
and 66 patients had swollen joints. The rheumatoid factor (RF) was positive in 78.3% and the
DAS28 was 3.2 ± 1.2. Our data emphasize that the AA genotype of rs11209026 was signiﬁcantly
associated with RA patients compared to the controls (p= 0.001). We did not ﬁnd any signiﬁcant
association between either rs2201841 or rs10889677 and the development of RA (p= 1, p= 0.56
respectively). The AA allele in the 3 SNPs were remarkable frequent in those with deformities and
positive RF.
Conclusion: Our results suggest that IL23 receptor AA genotype variant of rs11209026 contrib-
utes to the aetiology of RA and may be considered a genetic marker and shared the susceptibility
gene. We need to address the subgroup of patients who will beneﬁt from the selective suppression of
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patients by further studies.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Rheumatoid arthritis (RA) is a chronic progressive systemic
inﬂammatory autoimmune disease of the joints, which can lead
to long-term joint damage, resulting in chronic pain, loss of
function, and disability [1]. The pathogenesis of RA is multi-
farious, with suspected interrelated contributions from genetic,
infectious, environmental, and hormonal factors [2].
Advances in genotyping technology and the use of single-
nucleotide polymorphism (SNP) assays have facilitated the
application of whole genome association approaches to link
genetic variants with disease susceptibility [3]. Gene polymor-
phism of various cytokines have been importantly considered
in RA; The tumour necrosis factor-a (TNF-a) –308G/A pro-
moter polymorphism as well as interleukin-6 (IL-6) –174G/C
polymorphisms were signiﬁcantly detected in RA patients
and would predict the disease activity and functional status
[4,5].
IL-23 was found during a genome scan for the IL-6/IL-12
cytokine family. IL-23 is a heterodimer, sharing a p40 subunit
with IL-12 but having a distinct p19 subunit. IL-23 plays a
role in type 1-polarized T cell immune responses [6]. A role
of IL-23 has been implemented in the pathogenesis of many
rheumatic diseases; being overexpressed in psoriatic arthritis
and related to disease severity [7], and considered a critical
biomarker for the development of arthritis in inﬂammatory
bowel disease [8].
IL-23 binds to IL-12Rb1. The receptor for this cytokine is
heterodimeric and uses a novel second subunit, IL-23R, which
is a member of the hematopoietin receptor family [9]. Soon
researches were directed towards interleukin-23 receptor
(IL23R) gene polymorphism, which maps to chromosome 1.
The encoded protein forms a receptor for IL-23, together with
the b1 subunit of IL-12 (IL12Rb1) [10]. IL-23 and its gene
polymorphism played a signiﬁcant role in neuro-Behc¸et’s and
uveitis in Egyptian Behc¸et’s disease patients with a signiﬁcant
relation to disease activity, making both potential markers
[11]. IL-23R is a type I cytokine transmembrane protein, it
consists of 629 amino acids. The extracellular domain contains
a signal sequence, an N terminal Ig-like domain, and two
cytokine receptor domains [9]. Eleven exons encode for the
standard form of IL-23R. Through alternative splicing, they
can generate at least six spliced isoforms (IL- 23R1 to 6) [12].
Expression of IL-23 receptors occurs on activated or
memory T cells, on natural killer cells, and to a less extent
on macrophages and dendritic cells. The corresponding legend
cytokine, IL-23, is a key component of the immunoregulatory
pathway and plays an important role in the development,
differentiation, and effector functions of immune cells [13].
In chronic inﬂammation, the antigen-stimulated macro-
phages and dendritic cells produce IL-23. Binding of IL-23
to its receptor leads to the activation of Janus Kinases (Jak2
and Tyk2), which can phosphorylate IL-23R at discrete loca-
tions and thus form docking sites for signal transducers andactivators of transcription (STATs). The STATs are then
phosphorylated by the Jaks, and are thus capable of dimerising
and translocating to the nucleus where they inﬂuence the tran-
scription of key pro-inﬂammatory genes [14]. IL-23 promotes
the development of Th17 cells producing IL-17, which
enhances T cells and induces the production of several inﬂam-
matory mediators. IL-23 also stimulates dendritic cells and
macrophages in an autocrine/paracrine manner to generate
other pro-inﬂammatory cytokines, like IL-1, IL-6, and TNF-
a [15,16]. The pro-inﬂammatory cytokines IL-23 and IL-17
are present in RA synovial ﬂuid in increased levels [17,18].
IL-17 stimulates osteoclast differentiation by inducing the
expression of receptor activator of NF-jB legend (RANKL)
[19]. In addition, IL-17 directly stimulates osteoclastogenesis
from monocytes alone, via the TNF,-a or RANK–RANKL
pathway [20]. IL-17 is important in joint destruction in animal
models and in patients with RA [21,22].
Polymorphisms of IL23R are associated with numerous dif-
ferent autoimmune diseases like inﬂammatory bowel disease,
ankylosing spondylitis, Graves’ ophthalmopathy, and psoria-
sis [23–26]. Yet conﬂicting results from different researches
as regards the role of allelic variants or haplo-groups of
IL-23R in the development of RA were illustrated.
Therefore, we aimed in the current study to assess the
possible association of the IL23R p.Arg381Gln (rs11209026)
substitution, rs2201841 and rs10889677 variants with the
susceptibility for developing RA.
2. Patients and methods
We conducted this study on 120 patients with rheumatoid
arthritis diagnosed according to the (2010) ACR criteria for
the classiﬁcation of RA [27]. We selected our cases from the
Rheumatology and Rehabilitation and Internal Medicine
departments and their outpatient clinics of Cairo, Al Fayoum
and Zagazig, University hospitals; they were collected in the
period from March 2012 till April 2014. A hundred and twenty
apparently healthy volunteers matched for age and sex were
taken as a control group. All patients were subjected to full
history taking and thorough general and musculoskeletal
examination (age, sex, disease duration, age of onset, duration
of morning stiffness, presence of extra-articular manifestations
and their current treatment). The disease activity in RA
patients was assessed by the 28 joint count Disease Activity
Score (DAS 28) using the number of swollen and tender joints,
erythrocyte sedimentation rate (ESR) and patient’s global sta-
tus and pain evaluated by the visual analogue scale (VAS)
range from 0 to 100 mm [28].
Blood samples were drawn from the cubital vein in patients
and controls at the day of clinical examination after overnight
fasting. Blood samples were collected on EDTA tubes and
were stored at 20 C till the time of assay which was per-
formed for all samples at the same time. Erythrocyte sedimen-
tation rate (ESR), complete blood count (CBC), Rheumatoid
Table 1 Characteristics of the rheumatoid arthritis patients.
Characteristics of the rheumatoid arthritis patients (N= 120)
Age years 42.5 ± 13.4
Gender male/female 22/98
Disease duration years 5.2 ± 3.5
Joints deformity N (%) 35 (29.2)
Swollen joints N (%) 66 (55)
TLC ·103/ll 7.5 ± 2.8
ESR mm/1st hour 59.1 ± 37.5
RF positivity N (%) 94 (78.3)
DAS28 range (mean ± SD) 1.5–4.7 (3.2 ± 1.2)
TLC, total leucocytic count; ESR, erythrocyte sedimentation rate;
RF, rheumatoid factor; DAS28, disease activity score in 28 joints.
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analysis were done. The molecular analysis was performed
using DNA extracted from peripheral blood leukocytes of
the patients and control. We obtained oral consent after
proper orientation of the patients and volunteers about the
objectives of the study. The study was approved by the local
ethics committee prior to their inclusion in the study.
The rs11209026 (IL23R Arg381Gln) was genotyped using
Real-time PCR method using Light Mix Kit human IL23R
Arg381GlnKit produced under license from Roche Diagnos-
tics GmbH (TIB MOLBIOL GmbH, Berlin, Germany).
The rs2201841 and rs10889677 SNPs were genotyped sepa-
rately using PCR-RFLP method from Huber et al. [25].
Instead of using ﬂuorescently labeled forward primers, DNA
was ampliﬁed using the ordinary primer pairs (from Operon
Biotechnologies (GmbH/Bio campus, Germany).
Forward primer 50-GGCCTATGATTATGCTTTTTCC
TG-30, reverse primer 50- GAACATAACCCTATTGACAC
CCTG-30 for rs2201841 and forward primer 50- AGGGGATT
GCTGGGCCATAT-30 and reverse primer 50TGTGCCTGTA
TGTGTGACCA-30 for rs10889677. We added 2U to digest
ampliﬁcation products separately.
Statistical analysis: All patients’ data were tabulated, and
processed using Statistical package for sciences and society
(SPSS 12.0) (SPSS Inc. Chicago, USA). Quantitative variables
were expressed by mean and standard deviation (SD) and then
compared using Mann–Whitney U test for comparing two
independent variables and Kruskal–Wallis analysis for more
than two independent variables. We expressed Qualitative
variables by frequency and percentage and compared it using
the chi-square test or Fischer’s exact test. P value was consid-
ered signiﬁcant if less than 0.05. Odd ratio (OR) and their 95%
conﬁdence interval (CI) were calculated for the interleukin 23Table 2 Comparison of the allele and genotype frequencies betwee
SNP Genotype allele Cases (N= 120)
rs11209026 AA 114 (95)
AG 6 (5)
rs2201841 AA 104 (86.7)
AG and GG 16 (13.3)
rs10889677 AA 82 (68.3)
CC and AC 38 (31.7)
SNP, single-nucleotide polymorphism; OR, odds ratio; CI, conﬁdence inreceptors genotype using multivariate logistic regression
analysis.
3. Results
One hundred and twenty cases with RA were included in the
present study. They were 98 females and 22 males, their ages
ranged from 18 to 69 years with a mean of 42.5 ± 13.42 years,
disease duration ranged from one year to 15 years with a mean
of 5.24 ± 3.45 years. One hundred twenty age and sex
matched healthy controls were also enrolled in the study. They
were 95 females and 25 males, their ages ranged from 20 to
65 years with a mean 44.26 ± 12.36. Rheumatoid factor
(RF) was positive in 94 (78.3%) cases and 35 (29.16%) had
deformities. 66 (55%) patients had swollen joints; 18 (15%)
had 1 swollen joint, 15 (12.5%) had 2, 8 (6.7%) had 3, 14
(11.7%) had 4, 6 (5%) had 5 and 5 (4.2%) had 6 swollen joints.
At the time of the study, all patients were treated with
NSAIDs, 51 patients (42.5%) were maintained on a combina-
tion of methotrexate (MTX) and hydroxychloroquine, 62
(51.6%) were treated with a combination of MTX and leﬂun-
omide and 7 (5.8%) patients were maintained on a combina-
tion of leﬂunomide and steroids. Clinical and demographic
data of the RA patients are shown in Table 1.
We tested SNPs of interleukin-23 receptors rs11209026,
rs2201841, and rs10889677 for association with RA. Our
results revealed that the frequency of the AA genotypes of
rs11209026 was signiﬁcantly increased (95%) in the patients
compared with the controls (61.7%) (p= 0.001), OR (0.37)
with CI (0.26–0.57), while the allele and genotype frequencies
of rs2201841 and rs10889677 showed no association with RA
(p= 0.73, p= 0.56 – OR= 1.82, OR= 1.35 respectively).
The comparison of allele and genotype frequencies between
the control and RA cases has been illustrated in Table 2.
The AA genotype of the rs11209026 was detected in 95.7%
of RF positive patients and in 88.6% of those having defor-
mity. The frequency of the interleukin-23 genotypes and alleles
in cases with positive RF and deformity has been illustrated
in Table 3.
4. Discussion
Rheumatoid arthritis (RA) represents the most common form
of chronic inﬂammatory joint disease. The range of presenta-
tions of RA is broad; the clinical course can range from mild,
self-limiting arthritis to progressive multisystem inﬂammation.
The ﬁrst and most common manifestations are pain, stiffness
and swelling of peripheral joints. Though not directly lifen the rheumatoid arthritis patients and controls.
Controls (N= 120) p OR CI (95%)
74 (61.7) 0.001 0.37 0.26–0.57
46 (38.3)
104 (86.7) 1 1 0.23–4.43
16 (13.3)
89 (74.2) 0.56 1.35 0.43–3.83
33 (27.5)
terval.
Table 3 The frequency of the interleukin-23 receptor genotypes and alleles in rheumatoid arthritis patients with positive rheumatoid
factor and deformity.
IL-23 receptor genotypes in rheumatoid arthritis patients (N= 120)
SNP Genotype allele Positive RF (N= 94) Deformity (N= 35)
N (%) N (%)
rs11209026 AA 90 (95.7) 31 (88.6)
AG 4 (4.3) 4 (11.4)
rs2201841 AA 78 (83) 23 (65.7)
AG and GG 16 (17) 12 (34.3)
rs10889677 AA 55 (58.5) 25 (71.4)
CC and AC 39 (41.5) 10 (28.6)
SNP, single-nucleotide polymorphism; RF, rheumatoid factor.
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and has major economic consequences for society [2].
The strategies that guided us to select the studied gene were
based on choosing a susceptibility gene already identiﬁed in
other related diseases considering its relevant functions that
might be crucial in the pathogenesis of RA. In this study, we
selected the IL23 receptor (IL23R) as a candidate gene princi-
pally based on the fact that the interaction of IL23R with its
legend IL23 results in an increase of signal transducers and
activators of transcription signalling which can consequently
promote the production of IL17. IL17 is a potent pro-inﬂam-
matory cytokine already identiﬁed in various chronic inﬂam-
matory diseases [14]. Up-regulated production of IL23R that
is associated with certain SNP alleles in its gene could confer
risk for the disease [29].
The present study was performed to investigate the associ-
ation of three IL-23R gene SNPs in Egyptian RA patients. The
results showed that the AA genotype of the rs11209026 SNP
was signiﬁcantly associated with an increased susceptibility
to RA compared to the control (p= 0.001). However, there
was no signiﬁcant difference with regard to the genotypes of
rs7517847 and rs17375018 between patients and controls.
The signiﬁcant association demonstrated here is consistent
with earlier reports showing the relationship between the same
genotypic variant and other autoimmune diseases including
Behc¸et’s disease, psoriatic arthritis, inﬂammatory bowel
disease, and ankylosing spondylitis [23,24,30,31]. However,
others [10,32–34] have reported contradictory ﬁndings to our
result.
The biological impact of the investigated polymorphisms
on the expression and functionality of IL23R is currently
unknown but it is obvious that these SNPs can represent an
important link in the development of autoimmune and inﬂam-
matory diseases [13]. Several mechanisms are suggested by
which polymorphisms can change the function of the receptor.
The rs11209026 SNP is located in the cytoplasmic domain and
encodes the ﬁfth amino acid internal to the transmembrane
domain [35]. The arginine allele has a side chain with positive
charge while the rare glutamine has an uncharged polar one
and thus the substitution can have considerable effect on the
protein structure [13].
To investigate the relation of the other IL23R variants with
RA, we genotyped rs2201841 and rs10889677 SNPs in our RA
patients and controls. No signiﬁcant difference was found. It
has been reported that the rs10889677 located in the 30-UTR
can cause overexpression of the IL23R, driving differentiationof T-cells towards a Th17 subpopulation with an increased
release of other proinﬂammatory cytokines. The rs2201841 is
an intronic variant in signiﬁcant linkage disequilibrium with
rs10889677, and therefore is unlikely to confer an independent
risk [13]. The study on a Spanish Caucasian population
supports our ﬁndings [32]. On the other hand, a case–control
study on Hungarian Caucasian RA-patients and healthy
controls showed that both rs10889677 GG and rs2201841
GG are risk alleles in RA [36].
Like other candidate gene studies, there are several limita-
tions in our study. As the power to detect disease susceptibility
genes is inﬂuenced by the number of the patient’s samples, the
size of patient samples in our study seemed to be relatively
small. The results observed in this study need to be conﬁrmed
using a large sample size involving RA patients from different
areas in upper and lower Egypt.
In conclusion, our results suggest that IL23 receptor AA
genotype variant of rs11209026 would contribute to RA
aetiology; consequently, it might be a genetic marker for
RA. Further studies are needed to address the subgroup of
patients who will beneﬁt from the selective suppression of
the IL-23 signalling which would represent new perspectives
towards a personalized therapy of RA patients.
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